Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “(dual-target CAR-NK cells; selected antigen pair from GD2, MUC1, PSMA, mesothelin)”In the company’s words, NCT07589543 on ClinicalTrials.gov
- Tested for
- Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
- Main trialPhase 1/2
- “This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety/response follow-up.”In the company’s words, NCT07589543 on ClinicalTrials.gov
Other drugs for Epithelial Ovarian Cancer
- OregovomabCanariaBio Inc. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Torvutatug samrotecanAstraZeneca · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- BL-M07D1Sichuan Baili (Biokin, SystImmune) · Phase 3
Coming up1
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Mar 2027 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026